

# Supplementary Materials

**Table S1.** The detailed search strategy of databases.

**Table S2.** Website of guideline organizations and professional societies.

**Table S3.** Clinical guideline quality domains used in the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.

**Table S4.** Four items from the RIGHT (Reporting Item for Practice Guidelines in Healthcare) checklist to assess the conflicts of interest (COI).

**Table S5.** References of 15 included guidelines.

**Figure S1.** The AGREE II scores of six domains of the included 15 guidelines.

**Figure S2.** The distribution of AGREE II scores in the overall and six domains of 15 included guidelines.

**Table S1.** The detailed search strategy of databases.

PubMed	
#1	diabetes mellitus
#2	diabetes
#3	coronary artery disease
#4	stable coronary artery disease
#5	angina
#6	myocardial infarction
#7	acute coronary syndrome
#8	chronic coronary syndrome
#9	dual antiplatelet therapy
#10	anti-platelet agent
#11	anti-platelet drug
#12	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
#13	Guideline[ptyp]
#14	((("2009/01/01"[Date - Publication] : "3000"[Date - Publication])) AND English[Language])
#15	#12 AND #13 AND #14
Web of Science	
#1	TS=diabetes mellitus
#2	TS=diabetes
#3	TS=coronary artery disease
#4	TS=stable coronary artery disease
#5	TS=angina
#6	TS=myocardial infarction
#7	TS=acute coronary syndrome
#8	TS=chronic coronary syndrome
#9	TS=dual antiplatelet therapy
#10	TS=anti-platelet agent
#11	TS=anti-platelet drug
#12	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
#13	TI=guideline
#14	#12 AND #13 AND PY=2009-2019
EMBASE	
#1	'diabetes mellitus'
#2	'diabetes'
#3	'coronary artery disease'
#4	'stable coronary artery disease'
#5	'angina'
#6	'myocardial infarction'
#7	'acute coronary syndrome'
#8	'chronic coronary syndrome'
#9	'dual antiplatelet therapy'

#10	'anti-platelet agent'
#11	'anti-platelet drug'
#12	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
#13	'guideline':ti AND english:la AND [2009-2019]/py
#14	#12 AND #13

**Table S2.** Website of guideline organizations and professional societies.

ADA	<a href="https://www.diabetes.org/">https://www.diabetes.org/</a>
VA/DoD	<a href="https://www.va.gov/">https://www.va.gov/</a>
ACC	<a href="https://www.acc.org/">https://www.acc.org/</a>
AHA	<a href="https://www.heart.org/">https://www.heart.org/</a>
AACE	<a href="https://www.aace.com/">https://www.aace.com/</a>
ESC	<a href="https://www.escardio.org/">https://www.escardio.org/</a>
EASD	<a href="https://www.easd.org/">https://www.easd.org/</a>
NICE	<a href="https://www.nice.org.uk/">https://www.nice.org.uk/</a>
SIGN	<a href="https://www.sign.ac.uk/">https://www.sign.ac.uk/</a>
KDA	<a href="http://www.diabetes.or.kr/english/">http://www.diabetes.or.kr/english/</a>
TSOC	<a href="http://www.tsoc.org.tw/">http://www.tsoc.org.tw/</a>
JDS	<a href="http://www.jds.or.jp/">http://www.jds.or.jp/</a>
JCS	<a href="http://www.j-circ.or.jp/">http://www.j-circ.or.jp/</a>
CDA	<a href="https://www.diabetes.ca/">https://www.diabetes.ca/</a>
CCS	<a href="http://www.ccs.ca/en">http://www.ccs.ca/en</a>
NHFA	<a href="https://www.heartfoundation.org.au/">https://www.heartfoundation.org.au/</a>
Baker IDI	<a href="https://baker.edu.au/">https://baker.edu.au/</a>
IDF	<a href="https://www.idf.org/">https://www.idf.org/</a>

**Table S3.** Clinical guideline quality domains used in the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.

<b>Domains</b>	<b>Content</b>
D1: Scope and purpose (3 items)	<ol style="list-style-type: none"> <li>1. The overall objective(s) of the guideline is (are) specifically described.</li> <li>2. The health question(s) covered by the guideline is (are) specifically described.</li> <li>3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.</li> </ol>
D2: Stakeholder involvement (3 items)	<ol style="list-style-type: none"> <li>4. The guideline development group includes individuals from all relevant professional groups.</li> <li>5. The views and preferences of the target population (patients, public, etc.) have been sought.</li> <li>6. The target users of the guideline are clearly defined.</li> </ol>
D3: Rigor of development (8 items)	<ol style="list-style-type: none"> <li>7. Systematic methods were used to search for evidence.</li> <li>8. The criteria for selecting the evidence are clearly described.</li> <li>9. The strengths and limitations of the body of evidence are clearly described.</li> <li>10. The methods for formulating the recommendations are clearly described.</li> <li>11. The health benefits, side effects, and risks have been considered in formulating the recommendations.</li> <li>12. There is an explicit link between the recommendations and the supporting evidence.</li> <li>13. The guideline has been externally reviewed by experts prior to its publication.</li> <li>14. A procedure for updating the guideline is provided.</li> </ol>
D4: Clarity of presentation (3 items)	<ol style="list-style-type: none"> <li>15. The recommendations are specific and unambiguous.</li> <li>16. The different options for management of the condition or health issue are clearly presented.</li> <li>17. Key recommendations are easily identifiable.</li> </ol>
D5: Applicability (4 items)	<ol style="list-style-type: none"> <li>18. The guideline describes facilitators and barriers to its application.</li> <li>19. The guideline provides advice and/or tools on how the recommendations can be put into practice.</li> <li>20. The potential resource implications of applying the recommendations have been considered.</li> <li>21. The guideline presents monitoring and/or auditing criteria.</li> </ol>
D6: Editorial independence (2 items)	<ol style="list-style-type: none"> <li>22. The views of the funding body have not influenced the content of the guideline.</li> <li>23. Competing interests of guideline development group members have been recorded and addressed.</li> </ol>

**Table S4.** Four items from the RIGHT (Reporting Item for Practice Guidelines in Healthcare) checklist to assess the conflicts of interest (COI).

---

<b>Section:</b> Funding and declaration and management of interests	<b>Items</b>
Funding source(s) and role(s) of the funder	<ol style="list-style-type: none"><li>1. Describe the specific sources of funding for all stages of guideline development.</li><li>2. Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.</li></ol>
Declaration and management of interests	<ol style="list-style-type: none"><li>3. Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.</li><li>4. Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.</li></ol>

---


**Table S5.** References of 15 included guidelines.

ADA, 2019	American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. DIABETES CARE 2019, 42(Suppl 1): S103-S123.
AACE, 2015	Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21 Suppl 1:1-87.
ESC/EASD, 2019	Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019.
ESC, 2017	Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018;53:34-78.
ESC, 2016	Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23:NP1–NP96.
ESC, 2015	Roffi M, Patrono C, Collet J, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315.
NICE, 2015	National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. <a href="https://www.nice.org.uk/guidance/ng28">https://www.nice.org.uk/guidance/ng28</a> (2015). Accessed 2 Dec 2019.
SIGN, 2010	Healthcare Improvement Scotland (SIGN). Management of diabetes. <a href="https://www.sign.ac.uk/sign-116-and-154-diabetes.html">https://www.sign.ac.uk/sign-116-and-154-diabetes.html</a> (2010). Accessed 2 Dec 2019.
CDA, 2018	Canadian Diabetes Association. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. <a href="http://guidelines.diabetes.ca/cpg">http://guidelines.diabetes.ca/cpg</a> (2018). Accessed 2 Dec 2019.
CCS, 2011	Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2011;27 Suppl A:S1-S59.
RACGP, 2016	Royal Australian College of General Practitioners. General practice management of type 2 diabetes 2016-18. <a href="https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/management-of-type-2-diabetes">https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/management-of-type-2-diabetes</a> (2016). Accessed 2 Dec 2019.
Baker IDI, 2015	Baker Heart and Diabetes Institute. Secondary Prevention of Cardiovascular Disease in type 2 diabetes guideline. <a href="http://t2dgr.bakeridi.edu.au/">http://t2dgr.bakeridi.edu.au/</a> (2015). Accessed 2 Dec 2019.
JDS, 2016	Haneda M, Noda M, Origasa H, et al. Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig. 2018.
KDA, 2015	Korean Diabetes Association. 2015 Treatment Guidelines for Diabetes (5th edition). <a href="https://www.diabetes.or.kr/bbs/index.html?code=e_resource&amp;mode=tlst">https://www.diabetes.or.kr/bbs/index.html?code=e_resource&amp;mode=tlst</a> (2015).

	Accessed 2 Dec 2019.
IDF, 2012	International Diabetes Federation. Global Guideline for Type 2 Diabetes. <a href="https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes.html">https://www. idf. org//e-library/guidelines/79-global-guideline-for-type-2-diabetes.html</a> (2012). Accessed 22 Nov 2019.



**Figure S1.** The AGREE II scores of six domains of the included 15 guidelines.



**Figure S2.** The distribution of AGREE II scores in the overall and six domains of 15 included guidelines.

